

Additional C-type lectin receptors mediate interactions with *Pneumocystis* organisms and major surface glycoprotein

Theodore J. Kottom*, Eva M. Carmona, Kyle Schaeffbauer and Andrew H. Limper

Abstract

Introduction. Pathogen-associated molecular patterns' (PAMPs) are microbial signatures that are recognized by host myeloid C-type lectin receptors (CLRs). These CLRs interact with micro-organisms via their carbohydrate recognition domains (CRDs) and engage signalling pathways within the cell resulting in pro-inflammatory and microbicidal responses.

Gap statement. In this article, we extend our laboratory study of additional CLRs that recognize fungal ligands against *Pneumocystis murina* and *Pneumocystis carinii* and their purified major surface glycoproteins (Msgs).

Aim. To study the potential of newly synthesized hFc-CLR fusions on binding to *Pneumocystis* and its Msg.

Methods. A library of new synthesized hFc-CLR fusions was screened against *Pneumocystis murina* and *Pneumocystis carinii* organisms and their purified major surface glycoproteins (Msgs) found on the respective fungi via modified ELISA. Immunofluorescence assay (IFA) was implemented and quantified to verify results. mRNA expression analysis by quantitative PCR (q-PCR) was employed to detect respective CLRs found to bind fungal organisms in the ELISA and determine their expression levels in the mouse immunosuppressed *Pneumocystis* pneumonia (PCP) model.

Results. We detected a number of the CLR hFc-fusions displayed significant binding with *P. murina* and *P. carinii* organisms, and similarly to their respective Msgs. Significant organism and Msg binding was observed for CLR members C-type lectin domain family 12 member A (CLEC12A), Langerin, macrophage galactose-type lectin-1 (MGL-1), and specific intracellular adhesion molecule-3 grabbing non-integrin homologue-related 3 (SIGNR3). Immunofluorescence assay (IFA) with the respective CLR hFc-fusions against whole *P. murina* life forms corroborated these findings. Lastly, we surveyed the mRNA expression profiles of the respective CLRs tested above in the mouse immunosuppressed *Pneumocystis* pneumonia (PCP) model and determined that macrophage galactose type C-type lectin (*Mgl-1*), implicated in recognizing terminal N-acetylgalactosamine (GalNAc) found in the glycoproteins of microbial pathogens was significantly up-regulated during infection.

Conclusion. The data herein add to the growing list of CLRs recognizing *Pneumocystis* and provide insights for further study of organism/host immune cell interactions.

INTRODUCTION

Pneumocystis spp. cause *Pneumocystis* pneumonia (PCP) in mammalian hosts, and in humans *Pneumocystis jirovecii* pneumonia (PJP). *Pneumocystis* possess two dominant life

forms including the ascus (cyst), which contains β -1,3 and β -1,6 linked glucans, as well as surface-associated glycoprotein, termed major surface glycoprotein (Msg), and the more prevalent and diminutive trophic forms, which bears abundant amounts of Msg [1–3]. In previous studies, the

Received 27 July 2021; Accepted 22 October 2021; Published 10 December 2021

Author affiliations: ¹Thoracic Diseases Research Unit, Departments of Medicine and Biochemistry, Mayo Clinic College of Medicine, Rochester, MN, USA.

***Correspondence:** Theodore J. Kottom, kottom.theodore@mayo.edu

Keywords: pneumocystis; C-type lectin receptors (CLRs); carbohydrate recognition domains (CRDs); major surface glycoprotein (Msg).

Abbreviations: B2M, beta-2 microglobulin; CLRs, C-type lectin receptors; DC-SIGN, dendritic cell-specific intercellular adhesion molecule-3-grabbing non-integrin; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; ITIM, immunoreceptor tyrosine-based inhibitory motif; MCL, macrophage C-type lectin; MDL, myeloid DAP-12-associating lectin; MGL-1, macrophage galactose-type lectin-1; MR, mannose receptor; Msg/gpA, the major surface glycoprotein of *Pneumocystis*; Pc, *Pneumocystis carinii*; PCP, pneumocystis pneumonia; PJP, *Pneumocystis jirovecii* pneumonia; PRRs, pattern recognition receptors.

Two supplementary figures are available with the online version of this article.

001470 © 2021 The Authors



This is an open-access article distributed under the terms of the Creative Commons Attribution License.

authors and others have shown central roles of certain C-type lectin receptors (CLRs) in pro-inflammatory responses to *Pneumocystis*. Examples include CLRs Dectin-1 and macrophage-inducible C-type lectin (Mincle), where deletion of the respective genes results in significant increases in organism burden and subsequent mortality [4, 5]. In contrast, absence of Dectin-2 or the mannose receptor (MR) had no effect on organism burden, even though their deletion led to defective proinflammatory cytokine production and migration of phagocytic cells during PCP, respectively [6, 7]. CLRs also have the ability to ‘cross-talk’ with one another, leading to either increased or decreased proinflammatory responses, respectively [8–10]. Therefore, simple, single deletions of one CLR in a pathogenic fungal model, although informative, may not represent the full picture of host recognition and immune response to the organism during infection. In prior studies, we have screened and demonstrated that a number of previously implicated CLR-CRDs such as Dendritic Cell-Specific Intercellular adhesion molecule-3-Grabbing Non-integrin (DC-SIGN), Dectin-2, Macrophage C-type lectin (MCL), MR, and Mincle known to be important in host fungal interactions, also interacted with *Pneumocystis* to a significant degree [11]. In this study, we continue our screening of CLRs with a panel of newly synthesized hFc-fusion proteins against *Pneumocystis murina* and *Pneumocystis carinii* organisms and their respective isolated Msgs. In addition, immunofluorescence microscopy was implemented to verify CLR hFc-fusion binding to *P. murina*. Lastly, we surveyed the mRNA transcriptional profile in the mouse immunosuppressed PCP model of the most significant CLRs discovered in our initial solid-state CLR screening and report those results. Our data provide valuable quantitative and qualitative analysis of additional CLRs in *Pneumocystis* host immune recognition.

METHODS

Animals

All animal experiments were conducted in accordance with the guidance of the Mayo Institutional Animal Care and Use Committee. *P. murina* pneumonia was induced in mice immunosuppressed with GK 1.5 monoclonal antibody as previously described [12]. The GK1.5 antibody was obtained from Bio X Cell (Lebanon NH). Briefly, mice were given two intraperitoneal injections of 0.3 mg in 0.2 ml over the first week. Subsequently, mice were given weekly injections of the antibody for the 8–10 weeks. Organisms were purified as previously described [13]. The rat *P. carinii* pneumonia model has been described elsewhere [14]. Briefly, immunosuppression in rats was achieved by the addition of dexamethasone (1 mg l⁻¹) and tetracycline (500 mg l⁻¹) (both Sigma Aldrich) to prevent secondary bacterial infections. After 8–10 weeks of immunosuppression, rats were sacrificed and organism purified as previously described [15]. *Pneumocystis* glycoprotein termed Msg was prepared as characterized as previously reported [6]. Briefly, Msg preparations were run on PAGE gels and assessed by silver staining, demonstrating a distinct single band of the published molecular weight (MW) of Msg. Furthermore, Western blotting with a specific *Pneumocystis*

spp. anti-Msg monoclonal antibody (5E12), yielded a specific band at the appropriate MW [15].

CLR hFc-fusions

CLR human IgG1 Fc fragment (hFc)-fusions hFc control, mCLEC9A, mCLEC12A, mLangerin, myeloid DAP-12-associating lectin (mMDL), mMGL-1, and mSIGNR3 have been described previously [16]. Briefly, RNA from mouse spleen was isolated and converted to cDNA. PCR was then implemented to generate the extracellular region containing the ligand binding domain of the respective CLR. Next, fragments were cloned into pFuse-hIgG1-Fc (human) expression vector (InvivoGen, San Diego, CA) and transiently transfected into CHO-S cells. Fusion proteins were purified after 4 days utilizing HiTrap protein G HP columns (GE Healthcare, Piscataway, NJ). mMCL has been described and utilized by our lab previously and functioned as a positive binding control [11].

hFc-CLR fusion ELISA

Briefly, live mixed *P. murina* or *P. carinii* (~1×10⁶ life forms) were fixed in 4% paraformaldehyde, 0.1M K₂HPO₄, pH 6.5 for 90 min. The organisms were then washed three times with 0.1M K₂HPO₄, pH 6.5. These organisms or native *P. carinii* Msg (2.0 µg/well) or native *P. murina* Msg (0.2 µg/well) was plated onto 96-well microtitre plates and incubated at 4 °C overnight. The following day, plates were washed three times with 100 µl PBS-Tween (PBS-T). Next, wells were blocked with PBS/10% FBS/2.5% milk) at 4 °C for 2 h. After three washes with PBS-T, the respective CLR hFc-fusion proteins (200 ng) [16] were added in lectin binding buffer (LBB) (50 mM HEPES, 5 mM MgCl₂ and 5 mM CaCl₂) for 2 h at 4 °C. Next, 1 : 5000 dilution of HRP goat anti-human Ig Fc antibody (SouthernBiotech) in blocking buffer was added for 1 h at 4 °C. Lastly, after washing the plates three times with 1X PBS-T, 1X TMB substrate was applied for 20 min at RT, followed by stopping the reaction with 2.0 M H₂SO₄. Plates were read in a VERSAmax microplate reader (Molecular Devices) at 450 nm. Three to four independent experiments were conducted in duplicate wells for each assay.

Immunofluorescence studies

Briefly, mixed *P. murina* life forms were prepared as above for the solid-state ELISA. Organisms were next applied to poly-L-lysine coated slides for 15 min at RT. Slides were then washed with 1X PBS and incubated with 500 ng of the respective hFc-CLR fusion or hFc alone in LBB at 4 °C overnight. After washing three times in LBB, samples were incubated for 2 h with 1 : 250 Alexa Fluor 488 goat anti-human IgG (H+L) conjugated antibody (Life Technologies) at 4 °C. Finally, the slides were washed three times with 1X PBS, cover slips applied and viewed on an Olympus BX53 fluorescence microscope.

CLR mRNA expression during *P. murina* PCP model

Lungs were harvested after 10 weeks of *P. murina* infection and tissue samples (30 mg) were homogenized using a TissueLyser

Table 1. PCR primers used in this study

Gene name	Forward primer	Reverse primer
<i>Clec12A</i>	ACCATGTCCAAGGGTTCAG	AGTGGATATTGTGTGCGATCTT
<i>Langerin</i>	GTCTGAGGAAACCTCTCTGTATC	CACACGACCTTTTCAGTCTT
<i>Mcl</i>	TCAGACTACCACAGAGAGTAA	TCAGCAAGTCCCAGGAAATAAG
<i>Mgl-1</i>	GAACTCAAGGATCGAGGAGAAA	CTTTAGACAACACCACCTCCA
<i>Signr3</i>	GACTGATGAGGAGCAGACTTTC	GGATGGCTGGAATGATCTCAG
<i>B2M</i>	CTCGGTGACCCTGGTCTTTC	GGATTCAATGTGAGGCGGG
<i>Gapdh</i>	TTGCCATCAACGACCCCTTC	ACTCCAGCATACTCAGC

LT (Qiagen) at 50 oscillations/s for 5 min. Total RNA was isolated, and an aliquot (200 ng) was used to generate cDNA. Steady-state mRNA expression of the respective CLRs in these samples was determined by quantitative PCR (qPCR) analysis conducted with the respective primer sets (Table 1) and was expressed as normalized to Beta-2 microglobulin (*B2m*) or glyceraldehyde-3-phosphate dehydrogenase (*Gapdh*) to verify equal cDNA contents.

Statistical methods

All data are presented as mean \pm SD or SEM. Statistical testing was conducted between CLR hFc-fusions and the hFc control. Differences between conditions were first evaluated using ANOVA and subsequently unpaired Student's *t*-tests were performed on data sets. Statistics were performed using

GraphPad Prism version 9.2.0 software, and differences were considered to be statistically significant at $P < 0.05$.

RESULTS

CLR ELISA binding patterns

As previously described by our group [11], we implemented an ELISA-based method with a library of newly designed CLR hFc-fusion proteins against *P. murina* and *P. carinii* life forms and the organisms' abundant surface glycoproteins, Msgs. Using human hFc protein as a negative control, and the previously known interaction of *Pneumocystis* with CLR MCL as a positive control [11] we determined that CLEC12A, Langerin, MGL-1 and SIGNR3 displayed significant binding




Fig. 1. Binding of respective CRD Fc-fusion protein to *P. murina* organisms and *P. murina* major surface glycoprotein (Msg) as measured by absorbance at 450 nm. Total *P. murina* organisms or *P. murina* isolated Msg were applied to 96-well microtitre plates and probed with the respective hFc-fusion protein. * $P < 0.05$, ** $P < 0.005$.

to *P. murina* and *P. carinii* and their respective Msgs (Figs 1a, b and S1a, b, available in the online version of this article).

Correlation between ELISA and immunofluorescence results

Immunofluorescence assay (IFA) of the CLR hFc panel tested against immobilized *P. murina* life forms was conducted next. Visualization of these results confirmed the solid-state ELISA experiments, notably the respective CLR hFc-fusion panel bound *P. murina* with different fluorescent intensities as well as binding to different life forms present on the slides. No appreciable binding was observed for hFc, whereas the positive control MCL bound *P. murina* organisms similarly to our previously published data [11]. Our observations reveal that Langerin and SIGNR3 hFc-fusions bind both the cyst (white arrows) and trophic (red arrows) life forms similarly, whereas CLEC12A and MGL-1 hFc-fusions bind trophic forms with a high degree of selectivity, similar to the positive MCL control (Fig. 2). Fig. 2b shows the quantification of the fluorescence in graph form and also demonstrates that all the respective CLR fusions tested bind *P. murina* organisms with significance, similar to our solid-state ELISA binding assays above. The possible role and importance of all four of these CLRs are currently uncharacterized in PCP, and therefore data presented here provides an initial starting point for future studies to determine their roles in host immune recognition and downstream inflammatory signalling during PCP.

Enhanced mRNA expression of *Mgl-1* RNA CLR in the PCP model

Previous studies have indicated that CLR Mincle mRNA is elevated to a significant degree in *P. murina* infected mouse lung tissue compared with normal uninfected lung RNA. This observation was also noted in macrophages infected with bacteria *in vitro* as well as in bacterial and fungal pneumonia models. These data suggest a known importance for at least in part in these respective infection models [4, 17–20]. Therefore, in parallel fashion, we evaluated whether overall mRNA expression was increased in a mouse PCP infection model of the four CLRs of interest. Notably, and as confirmation of our previous findings [11], *Mcl* was significantly upregulated in the PCP rodent model. Of the four newly identified CLRs in *Pneumocystis* interactions, we determined *Mgl-1* mRNA was enhanced to a significant degree in *P. murina* infected lung tissue compared with normal uninfected lung RNA using *B2m* (Fig. 3) as well as *Gapdh* (Fig. S2) as reference genes.

DISCUSSION

Innate immune receptors bind fungi primarily through the carbohydrates embedding or lining the organism cell wall. The prototypic fungal cell wall is composed of chitin, β -1,3 and β -1,6 glucans, α -glucans, as well as a variety of mannoproteins [21]. Binding of these ligands via these pattern recognition receptors (PRRs) provide initial frontline defence and subsequent downstream modulation upon contact with micro-organisms [22]. Currently, there are more PRRs for


fungi than any other type of organisms [23]. Previously, we and others have shown a number of CLRs important for host immune response to *Pneumocystis*. These CLRs include Dectin-1, Dectin-2, Mincle, MR and DC-SIGN [4–6, 24, 25].

In this study we also demonstrated that all the CLRs that bound to *Pneumocystis* organisms bound *P. carinii* and *P. murina* organisms and their respective Msgs in similar fashion. The CLRs herein, typically recognize carbohydrate structure, which is much more conserved in fungi than, for example, their respective proteins [26]. We also have shown previously that the mouse CLR Dectin-2 can indeed bind isolated Msgs from both *P. carinii* and *P. murina* [6]. Therefore, most likely, mannan and glucan structures in *Pneumocystis* species have similar degrees of conservation and therefore account for the similar binding results we are seeing of these CLRs tested in both *P. carinii* and *P. murina*.

Looking at the CLRs in sequential order, CLEC12A an inhibitory CLR, contains an immunoreceptor tyrosine-based inhibitory (ITIM) motif in its cytoplasmic tail that can associate with SHP-1 and SHP-2, both signalling phosphatases [27]. Originally described as a uric acid crystal negative regulatory receptor involved in controlling noninfectious inflammation [28], recent studies also suggest a role in recognizing plasmodial hemozoin [29]. Hemozoin is a by-product of blood digestion from blood feeding parasites, such as malaria parasites caused by *Plasmodium* spp. Mice deficient in CLEC12A were protected from experimental cerebral malaria (ECM) [29]. Hemozoin is considered a viable drug target due to its requirement for malaria parasite survival and absence from the mammalian host. Anti-malarial drugs such as chloroquine bind hemozoin and block the addition of new haem groups to the growing crystal structure [30]. Although no known hemozoin-like crystal structures are known in *Pneumocystis*, researchers have demonstrated previously that chloroquine and analogues indeed have anti-*Pneumocystis* activity [31]. Further studies are needed to determine the *Pneumocystis* ligand(s) for CLEC12A and also its potential role in PCP.

Next, we observed significant binding of Langerin to both *Pneumocystis* life forms and Msg via the ELISA binding assay. Similarly, by IFA, Langerin CLR appears to bind both cystic and trophic forms. Langerin (CD207) is expressed exclusively by a subset of dendritic cells known as Langerhans cells [32]. Present in mucosal epithelium, they play an important role in invading microbial pathogens by binding antigens and migrating to draining lymph nodes to present antigens to T cells [33]. A number of pathogens including bacterial, viral and fungal are known to interact with Langerin [34]. From a fungal context, numerous studies have shown that the CLR binds to fungal mannose, GlcNAc and β -glucans from a number of pathogenic fungi [34]. Therefore, our results are as expected since *Pneumocystis* contains abundant β -glucan carbohydrate (cyst forms) as well as mannose containing protein such as Msg (trophic forms). The use of available selective Langerin DTR (diphtheria toxin receptor) mice to deplete Langerin cells would be of valuable interest

(a)



(b)




Fig. 2. (a) Soluble CLR hFc-fusions bind *P. murina* life forms as visualized by microscopy. (Left panels) Phase-microscopy image of *P. murina* life forms. (Right panels) *P. murina* organisms were stained with the Fc fragment alone or the respective CLR hFc-fusion, followed by staining and viewing with FITC-conjugated anti-human Fc antibody at 25 \times magnification. White arrows indicate cyst life forms, whereas red arrows indicate trophic life forms. (b) Bar graph of seven random similar sized rectangle fields of photos of the respective CLR hFc-fusions binding to *P. murina* life forms and graphed as fluorescence units. Analysis conducted with LI-COR Image Studio (version 5.2.5) software. * $P < 0.05$, ** $P < 0.005$, **** $P < 0.0001$.




Fig. 3. The expression of the respective CLRs during PCP. The mRNA expression levels of *Clec12A*, *Langerin*, *Mgl-1* and *Signr3* were determined in the animal infection model after 10 weeks of infection. *Mcl* was used as a positive control. The mRNA levels were quantified by qPCR and beta-2 microglobulin (*B2m*) used as a reference gene. A total of 9–11 mice were used per group tested. * $P < 0.05$, ** $P < 0.005$.

in determining the role of this cell type and receptor in the rodent PCP model [35].

The third CLR tested in this study that displayed significant binding was MGL-1. In mice there are two homologues of human MGL, MGL-1 and MGL-2, respectively. MGL in humans is expressed *in vivo* by DCs of the epidermis and lymph nodes, and *in vitro* of bone-marrow derived macrophages (BMDMs) [36]. MGL has reported to bind exclusively to terminal α - or β *N*-acetylgalactosamine (GalNAc or Tn) sequences [37]. MGL via the GalNAc terminated lipopolysaccharide (LPS) as well as glycoproteins bind bacteria such as *Neisseria gonorrhoeae*. These interactions lead to Th2 lineage via IL-4 production [38]. Mouse MGL-1 can recognize *N*-GalNAc and galactose [39]. Interestingly, *Pneumocystis* has indeed been shown to contain GalNAc residues [40]. Therefore, the role of the MGL mouse homologue MGL-1 in mouse PCP infection should be examined to determine if like similar CLRs Dectin-1 and Mincle its presence is needed to elicit proper host immune proinflammatory response and control of organism burden in the lung.

Lastly, we show appreciable binding of CLR SIGNR3 to *Pneumocystis* and *Msg*. SIGNR3 is the closest murine homologue to human DC-SIGN [41]. Previous reports show that this CLR can bind a number of microbial pathogens including *Mycobacterium tuberculosis* and *Candida albicans* [42]. Fungal ligands for SIGNR3 include zymosan and mannan [43]. In our previous CLR screen we demonstrated that human DC-SIGN also binds *Pneumocystis* organisms

as well as *Msg* [11]. These results were also reported by others [25]. Interestingly, it has been shown that although DC-SIGN can indeed bind the fungal organisms, this does not result in downstream activation. Lack of or weak affinity has been proposed as a reason why this occurs [25]. Previous researchers have shown that in the mouse dextran sulphate sodium (DSS)-induced colitis model, SIGNR3 deficiency can lead to exacerbated colitis, as well as an accompanying increase in TNF-alpha production. The authors conclude from their findings that SIGNR3 may be important in maintaining 'intestinal immune homeostasis' [43]. The finding that SIGNR3 indeed bind *Pneumocystis* significantly, provides further evidence of a possible role of DC-SIGN in PCP. Future studies should include conducting the PCP model in SIGNR3 knockout mice and determining whether this CLR is important in proper inflammatory response and control of organism burden in the lung.

In our last set of experiments, we examined the mRNA expression of the four respective aforementioned CLRs during PCP. As expected, and reported previously, *Mcl* was significantly upregulated in the 10-week PCP model [4] and served as a positive control for this analysis. Of the four CLRs tested, we determined that *Mgl-1* was also significantly upregulated in this model. Previous reports have shown that other CLRs involved in microbial infections including those with *C. albicans*, *Malassezia* spp. and *M. tuberculosis* are also upregulated during infection, and this increased upregulation may be important for control of the infection [17–20].

It should be noted that although we only saw significant increased expression of CLR *Mgl-1* in the PCP model, further individual time-point analysis of the other CLRs examined in this study early in the infection might show significant increases in mRNA expression. For example, in mouse lungs infected with *Streptococcus pneumoniae* the levels of Mincle mRNA steadily and significantly increase at 12 and 24 h post-infection but then decrease significantly to near baseline levels by 72 h post-infection suggesting early importance for this CLE in this infection [44]. It may very well be that the CLRs in this study may also display time-course-dependent expression levels as well at different points in PCP that may be critical for the infection. We have also noted increased mRNA expression of CLR Mincle during PCP, a critically important CLR in PCP to help control organism burden and proper inflammatory response [4]. In the future, we plan to determine the importance of MGL-1 by testing the PCP model in MGL-1-deficient mice. Specifically, others have shown that human MGL interacting with CD45 on CD4⁺ T cells can result in T-cell apoptosis leading to dampened inflammatory response and also concurrently activate IL-10 causing inhibition of cell maturation and migration [45]. It will be interesting therefore to determine if MGL-1 is needed in both immunocompetent as well as immunosuppressed models of PCP and importance in establishing or maintaining infection in these respective models.

The data presented here expand on our previous screening of CLR/*Pneumocystis* interactions and provide new possibilities for examining the role of these CLRs in PCP and how these novel binding events may contribute to the pathogenicity of *Pneumocystis* infection.

Funding information

This work was supported by the Mayo Foundation, the Walter and Leonore Annenberg Foundation, and NIH grant R01-HL62150 to AHL.

Acknowledgements

We would like to acknowledge Bernd Lepenies and Joao T. Monteiro from the Immunology Unit and Research Centre for Emerging Infections and Zoonoses, University of Veterinary Medicine, Hannover, Germany for the hFc-CLR fusions used in this study.

Author contributions

This project was designed by T.J.K.; PCP mouse infection model was conducted by K.S.; analysis of data was conducted by T.J.K, compilation and writing of the manuscript were done by T.J.K, E.M.C. and A.H.L. All authors approved the final version of the manuscript.

Conflicts of interest

The authors declare that there are no conflicts of interest.

Ethical statement

All animal experiments were reviewed, approved and conducted in accordance with the guidelines and oversight of the Mayo Institution Animal Care and Use Committee.

References

- Morris A, Lundgren JD, Masur H, Walzer PD, Hanson DL, et al. Current epidemiology of *Pneumocystis pneumonia*. *Emerg Infect Dis* 2004;10:1713–1720.
- Chabé M, Aliouat-Denis C-M, Delhaes L, Aliouat EM, Viscogliosi E, et al. *Pneumocystis*: from a doubtful unique entity to a group of highly diversified fungal species. *FEMS Yeast Res* 2011;11:2–17.
- Skalski JH, Kottom TJ, Limper AH. Pathobiology of *Pneumocystis pneumonia*: life cycle, cell wall and cell signal transduction. *FEMS Yeast Res* 2015;15:fov046
- Kottom TJ, Hebrink DM, Jenson PE, Nandakumar V, Wüthrich M, et al. The interaction of pneumocystis with the C-type lectin receptor mincle exerts a significant role in host defense against infection. *J Immunol* 2017;198:3515–3525.
- Saijo S, Fujikado N, Furuta T, Chung S, Kotaki H, et al. Dectin-1 is required for host defense against *Pneumocystis carinii* but not against *Candida albicans*. *Nat Immunol* 2007;8:39–46.
- Kottom TJ, Hebrink DM, Jenson PE, Marsolek PL, Wüthrich M, et al. Dectin-2 is a C-type lectin receptor that recognizes pneumocystis and participates in innate immune responses. *Am J Respir Cell Mol Biol* 2018;58:232–240.
- Swain SD, Lee SJ, Nussenzweig MC, Harmsen AG. Absence of the macrophage mannose receptor in mice does not increase susceptibility to *Pneumocystis carinii* infection *in vivo*. *Infect Immun* 2003;71:6213–6221.
- Iborra S, Martínez-López M, Cueto FJ, Conde-Garrosa R, Del Fresno C, et al. Leishmania uses mincle to target an inhibitory ITAM signaling pathway in dendritic cells that dampens adaptive immunity to infection. *Immunity* 2016;45:788–801.
- Wevers BA, Kaptein TM, Zijlstra-Willems EM, Theelen B, Boekhout T, et al. Fungal engagement of the C-type lectin mincle suppresses dectin-1-induced antifungal immunity. *Cell Host Microbe* 2014;15:494–505.
- Zhu LL, Zhao XQ, Jiang C, You Y, Chen XP, et al. C-type lectin receptors Dectin-3 and Dectin-2 form a heterodimeric pattern-recognition receptor for host defense against fungal infection. *Immunity* 2013;39:324–334.
- Kottom TJ, Hebrink DM, Monteiro JT, Lepenies B, Carmona EM, et al. Myeloid C-type lectin receptors that recognize fungal mannans interact with *Pneumocystis* organisms and major surface glycoprotein. *J Med Microbiol* 2019;68:1649–1654.
- Shellito J, Suzara VV, Blumenfeld W, Beck JM, Steger HJ, et al. A new model of *Pneumocystis carinii* infection in mice selectively depleted of helper T lymphocytes. *J Clin Invest* 1990;85:1686–1693.
- Vuk-Pavlovic Z, Mo EK, Icenhour CR, Standing JE, Fisher JH, et al. Surfactant protein D enhances *Pneumocystis* infection in immunosuppressed mice. *Am J Physiol Lung Cell Mol Physiol* 2006;290:L442–9.
- Sukura A, Kontinen YT, Sepper R, Lindberg LA. Recovery from *Pneumocystis carinii* pneumonia in dexamethasone-treated Wistar rats. *Eur Respir J* 1995;8:701–708.
- Limper AH, Hoyte JS, Standing JE. The role of alveolar macrophages in *Pneumocystis carinii* degradation and clearance from the lung. *J Clin Invest* 1997;99:2110–2117.
- Mayer S, Moeller R, Monteiro JT, Ellrott K, Josenhans C, et al. C-Type Lectin Receptor (CLR)-Fc fusion proteins as tools to screen for novel CLR/bacteria interactions: an exemplary study on preselected *Campylobacter jejuni* isolates. *Front Immunol* 2018;9:213.
- Wells CA, Salvage-Jones JA, Li X, Hitchens K, Butcher S, et al. The macrophage-inducible C-type lectin, mincle, is an essential component of the innate immune response to *Candida albicans*. *J Immunol* 2008;180:7404–7413.
- van den Berg LM, Gringhuis SI, Geijtenbeek TBH. An evolutionary perspective on C-type lectins in infection and immunity. *Ann N Y Acad Sci* 2012;1253:149–158.
- Devi S, Rajakumara E, Ahmed N. Induction of mincle by *Helicobacter pylori* and consequent anti-inflammatory signaling denote a bacterial survival strategy. *Sci Rep* 2015;5:15049.
- Rabes A, Zimmermann S, Reppe K, Lang R, Seeberger PH, et al. The C-type lectin receptor Mincle binds to *Streptococcus pneumoniae* but plays a limited role in the anti-pneumococcal innate immune response. *PLoS One* 2015;10:e0117022.
- García-Rubio R, de Oliveira HC, Rivera J, Trevijano-Contador N. The fungal cell wall: *Candida*, *Cryptococcus*, and *Aspergillus* species. *Front Microbiol* 2019;10:2993.

22. Browne EP. The role of toll-like receptors in retroviral infection. *Microorganisms* 2020;8:11.
23. Kirkland TN, Fierer J. Innate immune receptors and defense against primary pathogenic fungi. *Vaccines (Basel)* 2020;8:E303.
24. Ezekowitz RA, Williams DJ, Koziel H, Armstrong MY, Warner A, et al. Uptake of *Pneumocystis carinii* mediated by the macrophage mannose receptor. *Nature* 1991;351:155–158.
25. Sassi M, Kutty G, Ferreyra GA, Bishop LR, Liu Y, et al. The major surface glycoprotein of *Pneumocystis murina* does not activate dendritic cells. *J Infect Dis* 2018;218:1631–1640.
26. Camilli G, Tabouret G, Quintin J. The complexity of fungal β -glucan in health and disease: effects on the mononuclear phagocyte system. *Front Immunol* 2018;9:673.
27. Marshall ASJ, Willment JA, Lin H-H, Williams DL, Gordon S, et al. Identification and characterization of a novel human myeloid inhibitory C-type lectin-like receptor (MICL) that is predominantly expressed on granulocytes and monocytes. *J Biol Chem* 2004;279:14792–14802.
28. Neumann K, Castiñeiras-Vilariño M, Höckendorf U, Hanneschläger N, Lemeer S, et al. Clec12a is an inhibitory receptor for uric acid crystals that regulates inflammation in response to cell death. *Immunity* 2014;40:389–399.
29. Raulf M-K, Johannssen T, Matthiesen S, Neumann K, Hachenberg S, et al. The C-type lectin receptor CLEC12A recognizes plasmodial hemozoin and contributes to cerebral malaria development. *Cell Rep* 2019;28:30–38.
30. Coronado LM, Nadovich CT, Spadafora C. Malarial hemozoin: from target to tool. *Biochim Biophys Acta* 2014;1840:2032–2041.
31. Gomes A, Ferraz R, Ficker L, Collins MS, Prudêncio C, et al. Chloroquine analogues as leads against pneumocystis lung pathogens. *Antimicrob Agents Chemother* 2018;62:11.
32. Flacher V, Douillard P, Ait-Yahia S, Stoitzner P, Clair-Moninot V, et al. Expression of langerin/CD207 reveals dendritic cell heterogeneity between inbred mouse strains. *Immunology* 2008;123:339–347.
33. van Wijk F, Cheroutre H. Mucosal T cells in gut homeostasis and inflammation. *Expert Rev Clin Immunol* 2010;6:559–566.
34. de Jong MAWP, Vriend LEM, Theelen B, Taylor ME, Fluitsma D, et al. C-type lectin Langerin is a beta-glucan receptor on human Langerhans cells that recognizes opportunistic and pathogenic fungi. *Mol Immunol* 2010;47:1216–1225.
35. Bobr A, Olvera-Gomez I, Igyarto BZ, Haley KM, Hogquist KA, et al. Acute ablation of Langerhans cells enhances skin immune responses. *J Immunol* 2010;185:4724–4728.
36. Vázquez-Mendoza A, Carrero JC, Rodríguez-Sosa M. Parasitic infections: a role for C-type lectins receptors. *Biomed Res Int* 2013;2013:456352.
37. Zizzari IG, Napoletano C, Battisti F, Rahimi H, Caponnetto S, et al. MGL receptor and immunity: when the ligand can make the difference. *J Immunol Res* 2015;2015:450695.
38. van Sorge NM, Bleumink NMC, van Vliet SJ, Saeland E, van der Pol W-L, et al. N-glycosylated proteins and distinct lipooligosaccharide glycoforms of *Campylobacter jejuni* target the human C-type lectin receptor MGL. *Cell Microbiol* 2009;11:1768–1781.
39. Rodríguez T, Pacheco-Fernández T, Vázquez-Mendoza A, Nieto-Yañez O, Juárez-Avelar I, et al. MGL1 receptor plays a key role in the control of *T. cruzi* infection by increasing macrophage activation through modulation of ERK1/2, c-Jun, NF- κ B and NLRP3 pathways. *Cells* 2020;9:E108.
40. Yoshikawa H, Tegoshi T, Yoshida Y. Detection of surface carbohydrates on *Pneumocystis carinii* by fluorescein-conjugated lectins. *Parasitol Res* 1987;74:43–49.
41. Garcia-Vallejo JJ, van Kooyk Y. The physiological role of DC-SIGN: a tale of mice and men. *Trends Immunol* 2013;34:482–486.
42. Tanne A, Ma B, Boudou F, Tailleux L, Botella H, et al. A murine DC-SIGN homologue contributes to early host defense against *Mycobacterium tuberculosis*. *J Exp Med* 2009;206:2205–2220.
43. Eriksson M, Johannssen T, von Smolinski D, Gruber AD, Seeberger PH, et al. The C-Type lectin receptor SIGNR3 binds to fungi present in commensal microbiota and influences immune regulation in experimental colitis. *Front Immunol* 2013;4:196.
44. Behler-Janbeck F, Takano T, Maus R, Stolper J, Jonigk D, et al. C-type lectin mInCLE recognizes glucosyl-diacylglycerol of streptococcus pneumoniae and plays a protective role in pneumococcal pneumonia. *PLoS Pathog* 2016;12:e1006038:12..
45. van Vliet SJ, Gringhuis SI, Geijtenbeek TBH, van Kooyk Y. Regulation of effector T cells by antigen-presenting cells via interaction of the C-type lectin MGL with CD45. *Nat Immunol* 2006;7:1200–1208.

Five reasons to publish your next article with a Microbiology Society journal

1. The Microbiology Society is a not-for-profit organization.
2. We offer fast and rigorous peer review – average time to first decision is 4–6 weeks.
3. Our journals have a global readership with subscriptions held in research institutions around the world.
4. 80% of our authors rate our submission process as 'excellent' or 'very good'.
5. Your article will be published on an interactive journal platform with advanced metrics.

Find out more and submit your article at microbiologyresearch.org.